RMDN1

Across TCGA pan-cancer cohorts, RMDN1 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated RMDN1 data layer compared with 21 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher RMDN1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated RMDN1 expression acts as an unfavorable survival marker.

BRCA, CESC, and ACC are the cancer types where RMDN1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	OS	Median	All	0.198	0.924	<.001	36	view →
CESC	OS	Median	All	0.047	0.875	<.001	24	view →
ACC	OS	Median	All	0.140	0.623	.002	12	view →
SKCM	DFS	Median	II,III,IV	0.044	0.691	<.001	12	view →
SARC	DFS	Median	All	0.121	0.611	.041	6	view →
LUSC	DFS	Median	II,III,IV	0.185	0.717	.012	6	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

RMDN1–BRCA (OS)

Open the BRCA breakdown →